kawakami sign man final took healthier york franklinmyers china district officers wrote patients second type governor told aaron likely scores photos state technology tv experience basketball jets email congress 80

Articles for Bristol Myers

A new kind of drug for schizophrenia promises fewer side effects
2 months, 3 weeks ago

A new kind of drug for schizophrenia promises fewer side effects

NPR  

A new kind of drug for schizophrenia promises fewer side effects toggle caption Steve Belkowitz/Bristol Myers Squibb For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. “The dopamine hypothesis proposed that schizophrenia is associated with excessive dopamine neurotransmission — so too much dopamine activity,” says Dr. Ann Shinn, a …

Schizophrenia Patients Drug Miller Tiffany Sponsor Message Receptors
Big Pharma rallies and moves past obesity
4 months, 3 weeks ago

Big Pharma rallies and moves past obesity

Live Mint  

A market rotation is playing out across large pharmaceutical companies, with industry laggards such as Bristol Myers Squibb soaring in recent weeks and richly valued obesity plays Eli Lilly and Novo Nordisk sinking. Executives told analysts that despite the “net unfavorable impact" from the law in 2025, the company expects revenue to grow over 3% next year and then 5% …

Impact Earnings Pharma Lilly Bristol Myers
Drug giants eye China for deals despite growing Sino-US tensions
5 months ago

Drug giants eye China for deals despite growing Sino-US tensions

Hindustan Times  

* Drug giants eye China for deals despite growing Sino-US tensions Bristol Myers Squibb, Sanofi looking at China M&A -employees * AstraZeneca, Novartis have done China deals this year * Political risks are a consideration -analysts By Andrew Silver and Kane Wu SHANGHAI/HONG KONG, - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S. tensions, are scouring for deals …

China Companies Risk Company Deals Pharmaceutical Chinese
Senators ask CEOs why their drugs cost so much more in the U.S.
10 months, 2 weeks ago

Senators ask CEOs why their drugs cost so much more in the U.S.

NPR  

Senators ask CEOs why their drugs cost so much more in the U.S. Enlarge this image toggle caption Kevin Dietsch/Getty Images Kevin Dietsch/Getty Images Sparks flew on Capitol Hill Thursday as the CEOs of three drug companies faced questions from the Senate Committee on Health, Education, Labor and Pensions about why drug prices are so much higher in the United …

Japan Drugs Companies Prices Cost Committee Johnson
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
1 year ago

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Associated Press  

NEW YORK — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. “We expect KarXT to enhance our growth through the late 2020s and into the next decade,” Christopher Boerner, Bristol Myers Squibb CEO, said in a prepared statement, noting that the Karuna acquisition strengthens the company’s …

Billion Myers Bristol Bristol Myers Squibb Squibb Karuna Karxt
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio
1 year ago

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Please try again later {{ …

Billion Email Myers Bristol Bristol Myers Squibb Squibb Karuna
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
1 year ago

Bristol Myers to Buy Karuna Therapeutics for $14 Billion

Live Mint  

Drugmaker Bristol Myers Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Bristol Chief Executive Christopher Boerner said the acquisition would accelerate the company’s efforts to establish a beachhead in neuroscience drugs and power new sales growth as its older products begin losing patent protection and face lower-price competition. Boerner said KarXT’s approval would be the …

Drugs Billion Drug Bristol Bristol Myers Karuna Therapeutics